Targeted photodynamic therapy treatment of  in vitro  A375 metastatic melanoma cells

Channay Naidoo; Cherie Ann Kruger; Heidi Abrahamse

doi:10.18632/oncotarget.27221

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells

Channay Naidoo, Cherie Ann Kruger and Heidi Abrahamse

PDF | Full Text | How to cite

Oncotarget. 2019; 10:6079-6095. https://doi.org/10.18632/oncotarget.27221

Metrics: PDF 1458 views | Full Text 1852 views | ?

Abstract

Channay Naidoo1, Cherie Ann Kruger1 and Heidi Abrahamse1

1 Laser Research Centre, University of Johannesburg, Johannesburg, South Africa

Correspondence to:

Cherie Ann Kruger,

email:

[email protected]

Keywords: metastatic melanoma; nano active targeting; zinc phthalocyanine tetra-sulphonic acid; photodynamic therapy

Received: July 17, 2019 Accepted: August 17, 2019 Published: October 22, 2019

ABSTRACT

Metastatic Melanoma (MM) is a deadly form of skin cancer and many photodynamic therapy (PDT) studies have noted limitations in relation to effective photosensitizer (PS) drug uptake in tumors. The focus of this study was to develop a PS multicomponent nanoparticle drug conjugate carrier system which specifically targets MM cells via biomarkers to actively enhance PS delivery and so improve MM PDT. An antibody-metallated phthalocyanine-polyethylene glycol-gold nanoparticle drug conjugate, was successfully synthesized and characterized. PS active drug targeting PDT experiments at 673 nm were conducted within in vitro cultured MM. Results noted that this drug conjugate enhanced the PDT treatment of MM, through improved subcellular localization of the PS, as well as noted significantly improved cytotoxic and late apoptotic cellular death in cells. The results from this study demonstrate that through the bio-active antibody PS drug targeting of MM, the efficacy of PDT treatment for this cancer can be enhanced.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27221

Publication Alerts

Research Papers:

Targeted photodynamic therapy treatment of in vitro A375 metastatic melanoma cells

Abstract